RxDoctor Payments Data

Bruce Baskir, MD

Internal Medicine · Bridgeton, MONPI 1427165935

Payments from drug & device makers

$359in general payments, 2019–2025

Across 24 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$261
  • Pfizer$36
  • Gilead$33
  • Biohaven Pharmaceutical Holding Company Ltd.$16
  • Apria Healthcare LLC$13
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Food & beverage$359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$359 in reported general payments places this provider in the 55th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$48,491
Medicare patients
136
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$139,164
OzempicSemaglutide61$87,466
XifaxanRifaximin13$49,296
JanuviaSitagliptin Phosphate58$36,899
TrulicityDulaglutide22$29,346
JardianceEmpagliflozin32$25,859
SuboxoneBuprenorphine Hcl/Naloxone Hcl35$23,149
LinzessLinaclotide16$21,745
SymbicortBudesonide/Formoterol Fumarate50$19,489
Breo ElliptaFluticasone/Vilanterol16$16,752
ZubsolvBuprenorphine Hcl/Naloxone Hcl16$16,492
AptiomEslicarbazepine Acetate13$16,441
Lantus SolostarInsulin Glargine,hum.Rec.Anlog107$12,967
EntrestoSacubitril/Valsartan27$12,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$139,164213 claims
GSKBreo Ellipta, Trelegy Ellipta$261$26,93127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Bridgeton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →